Treatment sequencing and drug survival in pustulosis palmoplantaris: a real-world cohort study (EADV 2026) - Aug 6, 2026 - Abstract #P2278; AS-2572; Pres time: Sep 30, 2026; Location: ePoster Area; "Among therapies with n≥5, the most frequently used were apremilast (n=52), acitretin (n=41), ciclosporin (n=33), guselkumab (n=28), methotrexate (n=27), dimethylfumarate (n=19), fumaric acid esters (n=17), deucravacitinib (n=16), ixekizumab (n=10), bimekizumab (n=8), alitretinoin (n=7), and ustekinumab (n=5)...Kaplan–Meier analyses include therapies with ≥5 treatment episodes. Biologics and targeted therapies demonstrate more sustained treatment persistence compared to conventional systemic therapies."
Clinical • Real-world • Real-world evidence • Immunology
|
|
Sina Winkler; Ulrich Mrowietz; Sascha Gerdes
|